ScreenerHero

CGTX Cognition Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cogrx.com
0.9366USD-0.36%Mkt Cap: 89.06M $P/E: —

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central n…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap89.06M USD
Enterprise Value55.97M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-23.49M USD
Revenue/Share—
Last Price0.9366 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.27
PEG—
EV/EBITDA-1.53
EV/Revenue—
P/S—
P/B2.71
EPS (TTM)-0.17
EPS (Forward)-0.22
52W Range
0.550026% of range2.050
52W High2.050 USD
52W Low0.5500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-68.53%
ROA-48.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-26.89%
Net Debt-33.42M USD
Net Debt/EBITDA0.91
Balance Sheet
Debt/Equity0.02
Current Ratio7.03
Quick Ratio6.78
Book Value/Sh0.35 USD
Cash/Share0.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.333 USD
Upside (mean)+255.9%
Target Range3.000 USD – 4.000 USD
3.000+255.9% to mean4.000
# Analysts3
Ownership
Shares Out.95.09M
Float87.51M
Insiders1.29%
Institutions23.79%
Short Interest
Short Ratio21.0d
Short % Float8.78%
Short % Out.8.14%
Shares Short7.74M
Short (prev mo.)7.13M
Technical
SMA 500.9938 (-5.8%)
SMA 2001.130 (-17.1%)
Beta1.80
S&P 52W Chg16.45%
Avg Vol (30d)390.34K
Avg Vol (10d)422.92K
Technical Indicators
RSI (14)43.5
MACD-0.0221
MACD Signal-0.0198
MACD Hist.-0.0023
BB Upper1.045 USD
BB Middle0.9675 USD
BB Lower0.8902 USD
BB Width15.98%
ATR (14)0.0501 USD
Vol Ratio (20d)0.50x